FourKites Appoints New President Rocky Subramanian to Accelerate Global Expansion
Leading supply chain visibility company FourKites today announces the appointment of Rocky Subramanian as President, effective immediately. Widely respected as a trusted advisor to leaders executing complex digital transformation at organisations of all sizes, Subramanian will work alongside CEO Mathew Elenjickal to drive the company's strategy, growth and customer success globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230406005293/en/
FourKites announces the appointment of Rocky Subramanian as President (Photo: Business Wire)
“As our new President, Rocky will be key to taking FourKites to the next level,” said Elenjickal. “He has a proven track record in delivering big wins for customers, building world-class teams, championing workplace diversity and culture, scaling processes and growing thriving partner ecosystems. Just as important, he passionately shares my belief that better supply chains make the world a better place. I’m honoured to welcome him to our executive team as we accelerate FourKites’ growth trajectory.”
Subramanian was most recently Executive Vice President and CRO at Ceridian (NYSE:CDAY), where he helped the company grow to over $1.2B in revenue, added some of the biggest global brands as customers, and transformed the revenue organisation. He previously served as Senior Vice President and Managing Director of one of SAP’s (NYSE:SAP) largest market units — with responsibilities spanning sales, go-to-market strategy, operations and services for the entire enterprise software portfolio — which he grew to over $1.8B. Prior to SAP, Subramanian served in various roles at Oracle/PeopleSoft (NYSE:ORCL), Renaissance and NCS Pearson. He also advises as a volunteer mentor, and supports organisations with missions focused on education accessibility and eradicating hunger.
“From the beginning, I have been inspired by FourKites’ vision. It goes far beyond visibility; FourKites is helping companies lower costs, improve customer satisfaction, enhance workplace productivity and achieve their sustainability goals. It’s helping get food, medication and critical supplies to people who need them — faster and more reliably than ever before,” said Subramanian. “Paired with the company’s world-class products, pace of innovation, rapid deployment, thriving partner ecosystem and the scale at which we can help our customers, the potential for FourKites’ global impact is limitless. I’m excited and proud to join Matt and the entire FourKites team on this mission.”
Subramanian’s appointment comes on the heels of significant momentum for FourKites. In 2022, the company realised 70% growth in new customers, with more than 1,200 of the world’s most recognised brands — including 50% of the Fortune 500 — now using FourKites to track more than 3 million shipments around the world every day. In addition to strategic investments in 2021 from industry heavyweights Qualcomm Ventures, LLC, Volvo Group Venture Capital AB and Zebra Technologies, over the past year, FourKites inked strategic partnerships with a number of industry titans to continue executing on its bold vision to provide visibility everywhere. These companies include Mitsui & Co., Ltd., Quiet Platforms, Sony, Microsoft and Narvar. The real-time supply chain visibility pioneer was also recognised for its industry leadership and ongoing innovation by Gartner, SupplyChainBrain, Blue Yonder, Builtin Chicago, Manhattan Associates and Food Shippers of America.
FourKites continues to attract top talent to its senior leadership team as it scales its global operations and reinforces its focus on customer success. In addition to Subramanian, the company recently announced the appointment of Rebecca Nerad as Vice President of Global Customer Success, and Natalie Wolf, Vice President of Customer Operations and Strategy. Nerad has over 20 years in the supply chain industry, having held senior customer success roles at e2open, i2 Technologies, JDA Software and Bristlecone, while Wolf has held senior customer experience roles at Anaplan and Celonis.
About FourKites
Leading global supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 3 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 200 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,200 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230406005293/en/
Contact information
Scott Johnston
FourKites European PR Director
+31 62 147 8442
scott.johnston@fourkites.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
